New treatments for allergen immunotherapy

Akdis, Mübeccel

Abstract: Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30% of the population. Although applied for 100 years to cure allergy, SIT still faces several problems related to side effects and limited efficacy. Currently, allergen-SIT is performed with vaccines based on allergen extracts that can cause severe, often life threatening, anaphylactic reactions as well as new IgE sensitization to other allergens present in the extract. Low patient adherence and high costs due to long duration (3 to 5 years) of treatment have been commonly reported. Several strategies have been developed to tackle these issues and it became possible to produce recombinant allergen-SIT vaccines with reduced allergenic activity.

DOI: https://doi.org/10.1186/1939-4551-7-23

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-103528
Journal Article
Published Version

Originally published at:
Akdis, Mübeccel (2014). New treatments for allergen immunotherapy. World Allergy Organization Journal, 7:23.
DOI: https://doi.org/10.1186/1939-4551-7-23
New treatments for allergen immunotherapy

Mübeccel Akdis1,2

Abstract

Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30% of the population. Although applied for 100 years to cure allergy, SIT still faces several problems related to side effects and limited efficacy. Currently, allergen-SIT is performed with vaccines based on allergen extracts that can cause severe, often life threatening, anaphylactic reactions as well as new IgE sensitization to other allergens present in the extract. Low patient adherence and high costs due to long duration (3 to 5 years) of treatment have been commonly reported. Several strategies have been developed to tackle these issues and it became possible to produce recombinant allergen-SIT-vaccines with reduced allergenic activity.

Although performed for 102 years, allergen immunotherapy (AIT) faces several problems related to its efficacy, side effects, low patient adherence and the high costs due to long duration (3 to 5 years) of treatment [1,2]. The approaches to improve the efficacy and safety of vaccine-based AIT can be classified into different groups (Table 1).

Targeting T cells to induce T cell tolerance and bypassing IgE binding to avoid IgE-mediated side effects is the first approach [26]. T cell tolerance appears to be one of the key mechanisms of action of AIT [27]. The conformation dependence of B cell epitopes and linearity of the amino acids sequence of T cell epitopes in the three dimensional structure of an allergen has been targeted in this group using allergen-fragments, fusions, hybrids and chimeras [3,4,6,26]. The prototype of this approach is peptide immunotherapy that utilizes linear T cell epitope peptides [7,8,28]. A major advantage of these T cell targeting approaches is that higher doses of allergens to be sequentially administered, which is required to induce T cell tolerance without the risk of anaphylaxis [12,26]. In addition, recently allergen-specific B regulatory (reg) cells have been demonstrated to be important. It appears that these Breg cells increase within the first 3 months of AIT and differentiate into IgG4-producing plasma cells. IL-10 coming from both B and T cells seem to be essential in IgG4 production [29].

The second approach is the use of recombinant allergens or their mixtures, with the aim of partially reconstituting an allergen extract. For example, a mixture of five recombinant grass pollen allergens showed effectiveness in reducing symptoms and the need for symptomatic medication in people with allergies to grass pollen [13]. All treated subjects developed strong allergen-specific IgG1 and IgG4 antibody responses. In another study of recombinant (r) Bet v 1 clinical improvement was observed accompanied by marked increases in Bet v 1-specific IgG levels, which were higher in the rBet v 1-treated group than in the birch and nBet v 1-treated groups. The recombinant allergen also avoided new sensitizations. New IgE specificities were induced in 3 of 29 patients treated with birch pollen extract, but in none of the 32 rBet v 1-treated or 29 nBet v 1-treated patients. No severe systemic adverse events were observed in the rBet v 1-treated group [30]. There have been more than 10 clinical trials—all showing increased clinical efficacy compared to placebo group—completed by using recombinant allergens during the last decade [31,32]. Recombinant allergens provide a significant advantage in the problems of standardization of allergen extracts.

Another important approach is to physically couple allergens to stimulators of the innate immune response. This area is very open to future developments, as there are infinite possibilities for combinations owing to the existence of multiple immune stimulators and methods for coupling [14-18]. Notably, the time, intensity and tissue location of stimulation of the innate immune response by the allergen is decisive in the induction of tolerance or
Table 1 Novel vaccine development for allergen-SIT

| Type of the vaccine/approach                               | Description and mechanism                                                                                                                                                                                                 | Current status                                                                                                                                                                                                 |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fusion of major allergens [3] and chimeric allergens [4]   | Major allergens or their fragments are fused and expressed as a single recombinant protein. IgE binding is attenuated, T cell reactivity is preserved. Preventive effect on generation of IgE is demonstrated in mice.                            | Effects in human cell cultures and mouse models.                                                                                                                                                                |
| Hypoallergenic hybrid molecules [5]                        | Derived from Der p 1 and Der p 2, reduced IgE reactivity of hybrid proteins, induce higher T cell proliferation responses.                                                                                                    | Effects in human cell cultures and mouse models.                                                                                                                                                                |
| Fragments of major allergens [6]                           | Major allergen (Bet v 1) is divided into nonIgE binding fragments. IgE binding is attenuated and T cell reactivity is preserved.                                                                                             | A multi-center clinical trial has been finalized.                                                                                                                                                             |
| Peptide immunotherapy [7-11]                               | NonIgE binding T cell epitope peptides (Fel d 1, Api m 1) have been used in cat and bee venom allergy.                                                                                                                                                        | Several promising clinical studies have been performed. Safe and tolerable in cat allergies.                                                                                                                  |
| Unrefolded native or recombinant allergens [12]            | Major recombinant allergens (Api m 1, Bet v 1) are not refolded to the native conformation. This decreases or abolishes IgE binding, but preserves T cell reactivity.                                                       | Several studies reported promising results.                                                                                                                                                                |
| Polymers of major allergens [6]                            | Major allergen (Bet v 1) is trimered. Mast cell, basophil degranulation is attenuated, T cell reactivity is preserved in vitro.                                                                                                                                    | A multi-center clinical trial has been finalized.                                                                                                                                                            |
| Fusion with immune response modifiers                      |                                                                                                           |                                                                                                                                                                                                            |
| Targeting FcγRII [21,22]                                   | Fusion of allergens with human Fcγ has been reported to inhibit allergen-induced basophil and mast cell degranulation by crosslinking Fcγ and FcγRI receptors.                                                  | Human cell cultures and mouse models.                                                                                                                                                                        |
| Modular antigen translocation (MAT) vaccines [23]          | The fusion of transactivator of transcription (Tat) peptide to both truncated invariant chain and allergens is able to target antigens to the nascent MHC II molecules in the trans-golgi compartment.     | Clinical trial is finalized and demonstrated safety and efficacy with evidence of immune regulation.                                                                                                          |
| Pre-treatment with anti-IgE mAb before SIT [24,25]         | To reduce SIT induced side effects. To enable relatively rapid dose increase To use relatively high doses                                                                                                                                                    | Significantly fewer systemic allergic reactions, more patients were able to reach the target maintenance immunotherapy dose.                                                                                     |

**Bypassing IgE and targeting T cells**

**Allergens coupled to adjuvants**

| Type of the vaccine/approach                               | Description and mechanism                                                                                                                                                                                                 | Current status                                                                                                                                                                                                 |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mixture of several major recombinant allergens [13]       | A mixture of five recombinant grass pollen allergens (Phl p 1, Phl p 2, Phl p 5a, Phl p 5b, Phl p 6) reduced symptoms and need for symptomatic medication in grass pollen allergic patients. | One clinical trial reported promising results.                                                                                                                                                              |
| GpG oligonucleotide-conjugated allergens [14]              | Major allergen (Amb a 1) is bound to a toll-like receptor 9-triggering GpG oligonucleotide.                                                                                                                                | A large multicenter clinical trial did not reach endpoints, but the clinical efficacy was robustly demonstrated.                                                                                           |
| Allergens coupled to virus-like particles [15]             | Der p 1 coupled to highly repetitive virus capsule-like recombinant particles                                                                                                                                                | Rapid induction of high IgG antibody titers was observed in healthy human volunteers.                                                                                                                      |
| Carbohydrate-based particles [16]                         | Carbohydrate-based particles-bound rPhl p 5b induced a stronger antibody and cytokine responses.                                                                                                                           | In murine models.                                                                                                                                                                                           |
| Hypoallergenic vaccine based on allergen-derived peptides fused to hepatitis B PreS [17] | Recombinant fusion proteins show reduced allergic activity in basophil activation and no IgE reactivity.                                                                                                                  | In murine models.                                                                                                                                                                                           |
| Monophosphoryl lipid A (MPL) formulated with allergoid [18]| Pollen allergoid formulated with the Th1-inducing adjuvant monophosphoryl lipid A (MPL) facilitates short-term SIT.                                                                                                      | Results of clinical trials have been reported.                                                                                                                                                              |

**Novel routes of administration**

| Type of the vaccine/approach                               | Description and mechanism                                                                                                                                                                                                 | Current status                                                                                                                                                                                                 |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intralymphatic vaccination [19]                            | Allergen-SIT vaccines administered directly into a lymph node. The aim is to deliver high amounts of allergens into secondary lymphatic organs.                                                                            | Results of a clinical trial have been reported to show safety and efficacy.                                                                                                                                 |
| Epicutaneous vaccination [20]                             | High numbers of antigen presenting cells (LCs), non-vascularized area, safe, needle-free, and potentially self-administrable.                                                                                         | Clinical trial in grass pollen-induced rhinoconjunctivitis demonstrated safety and efficacy.                                                                                                                 |

**Fusion with immune response modifiers**

| Type of the vaccine/approach                               | Description and mechanism                                                                                                                                                                                                 | Current status                                                                                                                                                                                                 |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Targeting FcγRII [21,22]                                   | Fusion of allergens with human Fcγ has been reported to inhibit allergen-induced basophil and mast cell degranulation by crosslinking Fcγ and FcγRI receptors.                                                  | Human cell cultures and mouse models.                                                                                                                                                                        |
| Modular antigen translocation (MAT) vaccines [23]          | The fusion of transactivator of transcription (Tat) peptide to both truncated invariant chain and allergens is able to target antigens to the nascent MHC II molecules in the trans-golgi compartment. | Clinical trial is finalized and demonstrated safety and efficacy with evidence of immune regulation.                                                                                                          |
| Pre-treatment with anti-IgE mAb before SIT [24,25]         | To reduce SIT induced side effects. To enable relatively rapid dose increase To use relatively high doses                                                                                                                                                    | Significantly fewer systemic allergic reactions, more patients were able to reach the target maintenance immunotherapy dose.                                                                                     |

immune activation. For example, house dust mites can use Toll-like receptor 4 triggering in airway structural cells to induce asthma-like inflammation in mice [33]. It is expected that novel adjuvants may induce allergen-specific T cell tolerance with relatively less allergen doses and may direct the unwanted Th2 response towards a Tregulatory response in
an earlier time frame. However, so far these approaches did not end up with a fruitful outcome. The generation and maintenance of allergen-specific T-cell tolerance is a key step in healthy immune responses to allergens and successful AIT. Breaking of peripheral T-cell tolerance to allergens can lead to the development of allergies, but the mechanisms are not completely understood. It was recently demonstrated that certain innate immune response signals and proinflammatory cytokines, such as IL-1β, IL-6, TLR-4-ligands and TLR8-ligands break allergen-specific CD4 T-cell tolerance in normally unresponsive subjects, which might lead to the development or exacerbation of allergic diseases after encountering microbes or inflammatory conditions. The usage of novel adjuvants should be considered also in this perspective [34].

The fourth approach is varying routes of vaccine administration. A meta-analysis of the double-blind, placebo-controlled trials has shown that sublingual immunotherapy (SLIT) is clinically efficacious with a treatment benefit approximately half of that achieved with subcutaneous AIT [35]. Sustained disease-modifying effects of this type of therapy have been confirmed in large-scale randomized, double-blind, placebo-controlled trials as well as in children [36,37]. The immunological mechanisms of SLIT seem to be similar to subcutaneous AIT, although the magnitude of the change in most parameters is modest or no changes have been observed. Immune tolerance induced by SLIT is associated with Treg cells, IL-10 production, increases in sublingual Foxp3-expressing cells and elevated allergen-specific IgG4, IgA and serum inhibitory activity for IgE-facilitated allergen binding to B cells [38,39]. Recently, allergen-specific FOXP3+ Treg cells have been found in human lingual and palatine tonsils in humans, and these cells may participate in oral tolerance and SLIT [40]. Oral mucosal tissue is naturally tolerogenic, and does not show acute inflammation despite high levels of bacterial colonization, and shows rapid wound healing in the absence of scarring. A C-type lectin receptor, SIGNR-1 (also called Cd209b), helps to condition dendritic cells in the gastrointestinal lamina propria for the induction of oral tolerance in a model of food-induced anaphylaxis. These results suggest that sugar-modified antigens might be used to induce oral tolerance by targeting SIGNR1 and lamina propria DCs [41]. Recently the intralymphnode and epicutaneous routes have been tested. Both routes showed similar efficacy to subcutaneous injection immunotherapy in grass pollen allergy, but less applications and lower total doses of allergen were required using these routes [19,20]. Intralymphatic administration induced T cell responses with strong cytotoxic activity and IFN-γ production that conferred long-term protection against viral infections and tumors.

In another approach, the coaggregation of FcεRI and FcγRII receptors that inhibit FcεRI signaling and the fusion of allergens to human Fcγ have been reported to inhibit allergen-induced basophil and mast cell degranulation by crosslinking Fcγ and FcεRI receptors [21,22]. In a different approach, the major cat allergen Fel d 1 was cloned and expressed together with a human immune deficiency virus protein, TAT-derived membrane translocation domain, and a truncated peptide of the invariant chain (modular antigen translocation (MAT)-Fel d 1) [42]. This MAT-Fel d 1 vaccine is efficiently internalized and potently presented to T cells by antigen-presenting cells, and induced T cell responses at doses which were approximately 100x lower than those of the native allergens. In a double-blind, placebo-controlled clinical trial, the MAT-Fel d 1 vaccine with alum adjuvant was administered in three increasing doses (1 μg, 3 μg, 10 μg) intoinguinal, lymph nodes at 4 week intervals. In addition to a good safety profile, individuals who were allergic to cats and treated with the MAT-Fel d 1 vaccines became clinically tolerant to nasal challenge of cat dander extract in parallel with increased serum IgG4 [23]. The findings were not reproduced in another study of intralymphatic immunotherapy [43].

In addition to physical fusion, there is also a huge potential for combining conventional and novel methods of AIT with immune response modifiers. For example, anti-IgE combined with AIT has been evaluated in several studies [24], and resulted in a significant decrease in the risk of anaphylaxis caused by rush immunotherapy (a rapid dose increment approach to reach the maintenance dose as quick as possible) and improved rescue medication scores (the need for a rescue medication to suppress the symptoms: for example anti-histamines for allergic rhinitis) of AIT with a good safety profile [24,44]. In a recent study, eighteen weeks’ treatment of omalizumab in combination with AIT in patients with seasonal allergic rhinitis and comorbid seasonal allergic asthma reduced the symptom load during the treatment period but showed no prolonged effect during treatment with AIT only [25]. Combination strategies with biological immune response modifiers are expected to substantially expand the treatment scope of AIT. Overall, there has been tremendous progress in addressing the challenge of improving efficacy and safety of AIT, which is still the only approach for curing allergic diseases. In addition, this strategy is still open to further developments, which are expected to improve its application to other diseases related to dysregulation of the immune system.

**Conclusion**

Currently, allergen-specific immunotherapy is the only available curative treatment of allergic diseases as it can induce long-term allergen-specific immune tolerance using multiple mechanisms. AIT is beneficial for a significant
fraction of the treated individuals, however life-threatening side effects can occur. Due to the long duration of the treatment there is a problem with full adherence to the therapy. Whereas it can be curative in some individuals, there are non responders to treatment. To overcome these problems, it is crucial to develop advanced vaccines. In addition, the discovery of reliable biomarkers to select patients with a good clinical response is important. Notably, the AIT-based curative approaches may also be promising for the prevention of allergic disease. A greater understanding of the underlying disease mechanisms in allergic diseases could bring the possibility of cure in a larger patient population nearer to reality.

Competing interests
The author declares she has no competing interests.

Acknowledgement
Support for the dissemination of the WAO Immunotherapy and Biologics Online Monograph is provided by the following sponsors: Circassia, Boehringer-Ingelheim, and ORA Inc.

Received: 22 April 2014 Accepted: 24 July 2014
Published: 24 September 2014

References
1. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013, 131(1):108–126. e1283.
2. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blass M, Bonini S, Boussquet J, Calderon M, Compliat E, Durham SR, van Wijk LG, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosano N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, van Bever H, Vichyardon P, Wahn U, Yuzef O. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014, 76.
3. Kussief F, Karamlou F, Rhyner C, Schmid-Grendelmeier P, Salagiani M, Mannhart C, Akdis M, Soldatova L, Markovic-Housley Z, von Beust BR, Kundig T, Kerneny DMA, Blaser K, Crameri R, Akdis CA. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005, 115:323–329.
4. Kramloof F, Schmid-Grendelmeier P, Kussief F, Akdis M, Salagiani M, von Beust BR, Reimers A, Zumkehr J, Soldatova L, Houseky-Markovic Z, Muller D, Kundig T, Kerneny DMA, Spangford MD, Blaser K, Akdis CA. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005, 35:3268–3276.
5. Asturias JA, Ibarra J, Arica ML, Villal C, Ferrer A, Garnier PM, Vinueza JE, Sanz ML, Andreu C, Martinez A. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009, 39:1088–1098.
6. Niederberger V, Horak F, Vrta1a S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, Gafvelin G, Grioulund H, Purohit A, Suck R, Fiebig H, Cromwell O, Pauli G, van Hage-Hamsten M, Valenta R. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14677–14682.
7. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoeft A, Maillere B, Kay AB, Larche M. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011, 127:98–107.
8. Moldaver D, Larche M. Immunotherapy with peptides. Allergy 2011, 66:794–711.
9. Norman P, Ohmann J, Li J, Long AA, Creticos PS, Geffter MA, Shaked Z, Wood R, Eggleston P, Lichtenstein LM, Jones N. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996, 154:1623–1628.
10. Müller UR, Akdis CA, Fricker M, Akdis M, Bettens F, Blesken T, Blaser K. Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998, 101:747–754.
11. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:467–53.
12. Pee L, Reisinger J, Fieck M, Vrta1a S, Pauli G, van Hage M, Cromwell O, Gadermaier E, Egger C, Reider N, Horak F, Valenta R, Niederberger V. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007, 179:5309–5316.
13. Jutel M, Jaeger L, Suck R, Neyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005, 116:608–613.
14. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyerf V, Eiden JJ, Broide D. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445–1455.
15. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulinja A, Hennecke F, Sladko K, Jennings GT, Bachmann MF. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006, 117:1470–1476.
16. Thunberg S, Neiment-Andersson T, Cheng Q, Wernfeling M, Bergstrom U, Swedin L, Dahlen SE, Arner E, Scheinuis A, Karlsson MC, Gafvelin G, van Hage M, Gronlund H. Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitised mice. Allergy 2009, 64:919–926.
17. Niespodziana K, Focke-Tejkl M, Linhart B, Civa1 V, Blatt K, Valenta P, van Hage M, Gronlund H, Valenta R. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS1. J Allergy Clin Immunol 2011, 127:1562–1570. e1566.
18. Rosewich M, Schube1 J, Eickmeier O, Telles T, Rose MA, Schubert R, Zie1en S. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol 2010, 160:403–410.
19. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormak SJ, Simon J, Wutherland B, Crameri R, Graf N, Johansen P, Kundig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008, 105:17908–17912.
20. Senti G, Senti G, von Moos S, Tay F, Graf N, Sondergerg T, Johansen P, Kündig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2011, 121:129–135.
21. Zhu D, Kepley CL, Zhang M, Zhang K, Saxons A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002, 8:518–521.
22. Zhu D, Kepley CL, Zhang K, Tenada T, Yamada T, Saxons A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2003, 11:446–440.
23. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hotthorn LA, Gronlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kündig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012, 129(5):1290–1296.
24. Massanari M, Nelson H, Casale T, Busse W, Kianfard F, Geppa GP, Zelind RK. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010, 125:383–389.
25. Kopp MV, Hamelmann E, Bendiks M, Zie1en S, Kamin W, Bergmann KC, Klein C, Wahn U. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013, 24:427–433.
26. Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001, 22:175–179.
27. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014, 133:621–631.
28. Mackenzie KJ, Nowakowski DJ, Leech MD, McFarlane AJ, Wilson C, Fitch PM, O’Connor RA, Howie SE, Schwarze J, Anderton SN. Effector and central memory T helper 2 cells respond differently to peptide immunotherapy. Proc Natl Acad Sci U S A 2011, 111:6784–793.
29. van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Sollner S, Akdis DG, Rückert B, Akdis CA, Akdis M: IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013, 131:204–212.

30. Pauli G, Larsen TH, Rok S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schoedder JW, Mothes N, Spitzauer S, Montagut A, Galván S, Melac M, Andre C, Poulson LK, Malling HJ: Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951–960.

31. Cromwell O, Hafner D, Nandy A: Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011, 127:865–872.

32. Wild C, Wallner M, Hufraggi K, Fuchs H, Hoffmann-Sommergruber K, Breiteneder H, Scheiner O, Ferreira I, Wiedemann U: A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 2007, 62:33–41.

33. Hammad H, Chepela M, Peros F, Willart MA, Germain RN, Lambrecht BN: House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009, 15:410–418.

34. Kucukoezer UC, Palomares O, Rückert B, Jartti T, Puhakka T, Nandy A, Gemicioğlu B, Fahrner HB, Jung A, Deniz G, Akdis CA, Akdis M: Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol 2013, 131:875–885, e879.

35. Radulovic S, Wilson D, Calderon M, Durham S: Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740–752.

36. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Rii B, Dahl R: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010, 125(131–138):e131–137.

37. Bufe A, Eberle P, Frank-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weishäuer C, Kaiser F: Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009, 123:167–173, e167.

38. Bousquet J, Anto JM, Demoly P, Schünemann HJ, Togias A, Akdis M, Auffray C, Bachert C, Bieber T, Bousquet Pj, Casale TB, Cruz AA, Keil T, Lodrup Larsen KC, Maurer M, Ohta K, Papadopoulos NG, Roman Rodriguez M, Samollninski B, Agache I, Andrianarisoa A, Ang CS, Annesi-Maesano I, Ballester F, Baena-Cagnani CE, Basagaña X, Bateman ED, Behl E, Bedbrook A, et al: Severe chronic allergic (and related) diseases: a uniform approach—a MeDALL–GA2LEN–ARIA position paper. Int Arch Allergy Immunol 2012, 158:216–231.

39. Allam JP, Peng WM, Appel T, Wenghofer M, Niederhaßgen B, Bieber T, Benge S, Novak N: Toll-like receptor 4 ligation enhances tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008, 123:368–374, e361.

40. Palomares O, Rückert B, Jartti T, Kucukoezer UC, Puhakka T, Gomez E, Fahrner HB, Speiser A, Jung A, Kwok WW, Kalogjera L, Akdis M, Akdis AC: Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012, 129:510–520.

41. Zhou Y, Kawasaki H, Hsu SC, Lee RT, Yao X, Plunkett B, Fu J, Yang K, Lee YC, Huang SK: Oral tolerance to food-induced systemic anaphylaxis mediated by the C-type lectin SIGNR1. Nat Med 2010, 16:1128–1133.

42. Cramer R, Kundig TM, Akdis CA: Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009, 9:568–573.

43. Witten M, Malling HJ, Blom L, Poulson BC, Poulson LK: Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013, 132:248–252, e1245.

44. Künker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JH: Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007, 120:688–695.

doi:10.1186/1939-4551-7-23
Cite this article as: Akdis: New treatments for allergen immunotherapy. World Allergy Organization Journal 2014 7:23.